Side-by-side comparison of AI visibility scores, market position, and capabilities
Boston Class A urban office REIT (NYSE: BXP) ~$3B revenue; CBD portfolio 90.9% occupied, 291 leases (5.6M sq ft, 9.8-yr avg term) in 2024, life sciences segment, competing with SL Green and Vornado.
BXP, Inc. (formerly Boston Properties) is a Boston, Massachusetts-based premier Class A office real estate investment trust — publicly traded on the New York Stock Exchange (NYSE: BXP) as an S&P 500 Real Estate component — owning, developing, and managing a portfolio of approximately 52 million square feet of premier workplaces in Boston, New York (midtown Manhattan), San Francisco, Washington D.C., Seattle, and Los Angeles through approximately 850 employees, serving marquee corporate tenants including financial institutions, law firms, technology companies, life sciences companies, and government agencies. In fiscal year 2024, BXP's CBD (Central Business District) portfolio was 90.9% occupied and 92.8% leased, with the company executing 291 leases totaling 5.6 million square feet at a 9.8-year weighted-average lease term — a long average lease term that reflects the high-quality nature of BXP's tenant base (investment-grade corporations committing to long-term office locations). BXP strengthened its balance sheet by addressing debt maturities and accessing capital markets to extend its liquidity profile. CEO Owen Thomas leads BXP through the post-pandemic office market recalibration — navigating the transition from hybrid/remote work disruption to a stabilized new equilibrium where Class A premier office space in transit-connected urban CBDs commands occupancy and rent premiums over commodity suburban office that has suffered secular vacancy growth. BXP rebranded from Boston Properties to BXP in 2023 to reflect its national multi-market portfolio.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.